Blood test for dementia, Parkinson's to hit market soon

Share this content:
A blood test that diagnoses Alzheimer's disease, Parkinson's and other neurodegenerative diseases with over 90% accuracy could be on the market as early as this summer, according to a report from the Society of Chemical Industry.

An Oklahoma-based company, Power3 Medical Products, has developed the test to measure the relative levels of 59 different protein biomarkers in the blood. NuroPro, as the test is called, can then distinguish between the different diseases. This would be the first diagnostic test for these types of disorders ever available, according to the company. Currently, diagnoses are made based on symptoms.

The test will first be available in Greece, and may not hit the U.S. market until the third or fourth quarter of this year, the company said. The test is currently undergoing clinical validation trials before being made available in either country.